甲福明损害了林西尼布对卵巢癌细胞系的抗瘤作用
Diana Luísa Almeida-Nunes1,2,3, João P N Silva4, Mariana Nunes3,5
1Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.
International journal of molecular sciences
|November 27, 2024
概括
林西尼布和美特福林联合治疗显示出对抗作用,降低了卵巢癌细胞的抗癌疗效. 需要进一步的研究,以找到用于卵巢癌治疗的协同作用剂.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 卵巢癌 (OC) 是女性癌症死亡的主要原因.
- 准胰岛素样生长因子1 (IGF-1) 信号通路是OC的一种有前途的治疗策略.
- 林西尼布 (IGF-1受体抑制剂) 和甲福明 (具有抗癌特性的抗糖尿病药物) 是OC治疗的潜在药物.
研究的目的:
- 为了研究林西替尼和美特福明对OVCAR3卵巢癌细胞的抗癌作用.
- 通过向IGF-1信号通路来评估这些药物的组合疗法的疗效.
- 评估IGF-1信号传递在OC细胞增殖中的作用.
主要方法:
- 使用siRNA介导的IGF-1基因沉默来抑制IGF-1信号通路.
- 用基于resazurin的测试来评估细胞活力.
- 细胞亡通过流动细胞计测量.
- 协同效应使用SynergyFinder 2.0软件进行了评估.
主要成果:
- 林西替尼和美特福明的组合显示出对抗作用,降低了它们在OC细胞系中的抗瘤疗效.
- 林西尼布单独显示出对OC的潜在治疗前景.
- 这项研究强调了需要协同作用的药物来增强林西替尼的疗效.
结论:
- 由于对抗性相互作用,林西替尼和甲福明的组合治疗卵巢癌是不有效的.
- 林西尼布作为治疗卵巢癌的单一疗法具有前景.
- 未来的研究应该专注于识别与林西替尼 (linsitinib) 协同作用的药物,例如标准化疗 (碳波拉丁,帕克利塔克塞尔),以改善卵巢癌的治疗结果.
更多相关视频
10:39Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
13.1K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.8K
相关概念视频
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
01:23Dipeptidyl Peptidase 4 Inhibitors
171
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
171
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K